regulatory
confidence high
sentiment positive
materiality 0.70
FDA grants RMAT designation to Rocket Pharma's RP-A601 gene therapy for PKP2-ACM
ROCKET PHARMACEUTICALS, INC.
- FDA granted RMAT designation for RP-A601 (AAV-based gene therapy) for PKP2-arrhythmogenic cardiomyopathy.
- RMAT provides expedited FDA review, early interactions, and potential accelerated approval.
- Phase 1 data: two patients with low baseline PKP2 showed 110% and 398% increases in protein expression.
- Improvements in right ventricular function, ventricular arrhythmias, and KCCQ-12 scores (34-41 pts).
- Fifth RMAT designation for Rocket; favorable safety with no dose-limiting toxicities.